Veraxa Biotech AG - Post de-SPAC VRXA Balance Sheet (2024-2025)

NASDAQ VRXA
$1.65 +0.06 (+3.77%)
At close: Sep 10, 2026 · 4:00 PM EDT
Reported Financials

Veraxa Biotech AG - Post de-SPAC Quarterly Balance Sheet

Periods 2 quarters
Latest Dec 2025

Veraxa Biotech AG - Post de-SPAC reported total assets of $101.12M and total liabilities of $120.85M for the quarter ended Dec 2025. This balance sheet covers 2 quarters of results from Dec 2024 through Dec 2025, standardized by Business Quant from the company’s SEC filings.

1Y3Y5Y7Y10YAll
Download Data
Balance Sheet Dec2024 Dec2025
Assets
Current Assets
Cash & EquivalentsCash & Equiv. 6.12M2.02M
Short-term InvestmentsInvestments (Current) 0.18M1.39M
Cash & Current Investments 6.30M3.41M
Receivables - OtherOther Receivables -0.12M0.06M
Prepaid Assets 0.08M0.13M
Current Assets 6.40M3.61M
Non-Current Assets
Property, Plant & Equipment (Net)PP&E (Net) 2.24M2.48M
Goodwill 26.08M28.59M
Intangibles 61.05M64.95M
Goodwill & Intangibles 94.35M103.41M
Long-Term Deferred Tax 1.60M2.05M
Non-Current Assets 90.36M97.51M
Assets 96.76M101.12M
Liabilities
Current Liabilities
Accounts Payables 0.56M1.74M
Notes Payables 1.25M
Payables 0.56M2.99M
Accumulated Expenses 2.06M3.35M
Other Accumulated Expenses 0.11M1.61M
Short term Debt 2.40M3.63M
Current Leases 0.18M0.32M
Total Current Liabilities 2.91M8.27M
Non-Current Liabilities
Non-Current Deferred Tax LiabilityNon-Current Deferred Tax 17.31M18.07M
Operating Leases 0.81M1.11M
Total Non-Current Liabilities 58.41M112.57M
Total Liabilities 61.31M120.85M
Shareholder's Equity
Total Debt 2.40M4.88M
Common Equity 35.45M-19.73M
Liabilities and Shareholders Equity 96.76M101.12M
Retained Earnings -36.37M-123.21M